Development of a scintillation proximity assay for β-ketoacyl-acyl carrier protein synthase III
Development of a scintillation proximity assay for β-ketoacyl-acyl carrier protein synthase III
复制标题
DOI:
10.1006/abio.2000.4594
复制
发表时间:
2000-06-15
影响因子:
2.9
通讯作者:
Reynolds, KA
中科院分区:
文献类型:
--
作者:
He, X;Mueller, JP;Reynolds, KA
Assays of beta-ketoacyl-acyl carrier protein synthases III (KASIII; FabH), a key enzyme initiating bacterial type II fatty acid biosynthesis, usually involve incubation of radiolabeled acetyl-coenzyme A and malonylacyl carrier protein (MACP). The radiolabeled acetoacetyl-ACP product is precipitated and separated from the substrate before quantitation. We have developed a scintillation proximity assay (SPA) where use of biotinylated MACP (BMACP) allows the generation of a biotinylated acetoacetyl-ACP, This product, when captured by the streptavidin-coated scintillant-impregnated microspheres, generates an SPA signal. A BMACP K-m of 7.1 mu M was determined using this SPA with the Streptomyces glaucescens FabH. A similar MACP K-m (6 mu M) was determined in a precipitation assay, demonstrating that BMACP is an effective substrate for FabH. IC50 values of 15.2 mu M (SPA) and 24.8 mu M were obtained with iodoacetamide and the S. glaucescens FabH, Comparable IC50 values of 160 mu M (SPA) and 125 mu M were also obtained with the antibiotic thiolactomycin and the Escherichia coli FabH. These observations demonstrate that FabH inhibitors can be readily detected using a SPA with BMACP and that the effectiveness of inhibitors in the SPA is comparable to that obtained using MACP and a standard TCA precipitation assay. A FabH SPA adaptable to high-throughput screening should facilitate the discovery of potential novel antibiotics. (C) 2000 Academic Press.